114 related articles for article (PubMed ID: 38129175)
1. [Expression of ProEXC and PRMT5 in cervical adenocarcinoma and their clinical significance].
Cui HX; Lou XL; Xia W; Zhang YS; Cheng XY; Deng LF
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(48):3967-3971. PubMed ID: 38129175
[TBL] [Abstract][Full Text] [Related]
2. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.
Jiang Y; Yuan Y; Chen M; Li S; Bai J; Zhang Y; Sun Y; Wang G; Xu H; Wang Z; Zheng Y; Nie H
Theranostics; 2021; 11(18):9162-9176. PubMed ID: 34522232
[No Abstract] [Full Text] [Related]
3. Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
Ibrahim R; Matsubara D; Osman W; Morikawa T; Goto A; Morita S; Ishikawa S; Aburatani H; Takai D; Nakajima J; Fukayama M; Niki T; Murakami Y
Hum Pathol; 2014 Jul; 45(7):1397-405. PubMed ID: 24775604
[TBL] [Abstract][Full Text] [Related]
4. Utility of ProExC and IMP3 immunocytochemical staining in atypical glandular cells of undetermined significance in liquid-based cervical cytology.
Lastra RR; Ou JJ; Reilly ME; Lawrence WD; Baloch ZW; Brooks JS; Barroeta JE
Diagn Cytopathol; 2014 May; 42(5):375-9. PubMed ID: 23904388
[TBL] [Abstract][Full Text] [Related]
5. ProExC is a novel marker for distinguishing between primary endometrial and endocervical adenocarcinomas.
Esheba GE
J Egypt Natl Canc Inst; 2013 Jun; 25(2):87-93. PubMed ID: 23719407
[TBL] [Abstract][Full Text] [Related]
6. B3GNT3 Expression Is a Novel Marker Correlated with Pelvic Lymph Node Metastasis and Poor Clinical Outcome in Early-Stage Cervical Cancer.
Zhang W; Hou T; Niu C; Song L; Zhang Y
PLoS One; 2015; 10(12):e0144360. PubMed ID: 26709519
[TBL] [Abstract][Full Text] [Related]
7. Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens.
Sanati S; Huettner P; Ylagan LR
Int J Gynecol Pathol; 2010 Jan; 29(1):79-87. PubMed ID: 19952938
[TBL] [Abstract][Full Text] [Related]
8. Expression profiles of ProEx C and Ki67 in squamous cell carcinoma in situ of the skin and their relationship with human papillomavirus genotypes.
Sánchez-Hernández M; Conesa-Zamora P; García-Solano J; Corbalán-Vélez R; Martínez-Barba E; Pérez-Guillermo M
J Cutan Pathol; 2010 Jul; 37(7):730-6. PubMed ID: 20184667
[TBL] [Abstract][Full Text] [Related]
9. BD-ProExC as adjunct molecular marker for improved detection of CIN2+ after HPV primary screening.
Depuydt CE; Makar AP; Ruymbeke MJ; Benoy IH; Vereecken AJ; Bogers JJ
Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):628-37. PubMed ID: 21297040
[TBL] [Abstract][Full Text] [Related]
10. MCM2/TOP2A (ProExC) immunohistochemistry as a predictive marker in head and neck mucosal biopsies.
Jenson EG; Baker M; Paydarfar JA; Gosselin BJ; Li Z; Black CC
Pathol Res Pract; 2014 Jun; 210(6):346-50. PubMed ID: 24630889
[TBL] [Abstract][Full Text] [Related]
11. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis.
Qin Y; Hu Q; Xu J; Ji S; Dai W; Liu W; Xu W; Sun Q; Zhang Z; Ni Q; Zhang B; Yu X; Xu X
Cell Commun Signal; 2019 Mar; 17(1):30. PubMed ID: 30922330
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of p16 and ProExC immunostaining in the detection of high-grade cervical intraepithelial neoplasia and cervical carcinoma.
Guo M; Baruch AC; Silva EG; Jan YJ; Lin E; Sneige N; Deavers MT
Am J Clin Pathol; 2011 Feb; 135(2):212-20. PubMed ID: 21228361
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of σ1 receptor over-expression in cervical cancer and the effect of its synthetic ligands on the growth of cervical cancer cells].
Deng YQ; Zhou XH; Jiang LL; Tang XJ; Zhang YX; Cui JQ
Zhonghua Fu Chan Ke Za Zhi; 2017 Jul; 52(7):473-482. PubMed ID: 28797155
[No Abstract] [Full Text] [Related]
14. Predictive value of p16
Ding L; Song L; Zhao W; Li X; Gao W; Qi Z; Wang J
Exp Ther Med; 2020 Apr; 19(4):2457-2466. PubMed ID: 32256722
[TBL] [Abstract][Full Text] [Related]
15. TOP2A/MCM2, p16
Del Moral-Hernández O; Hernández-Sotelo D; Alarcón-Romero LDC; Mendoza-Catalán MA; Flores-Alfaro E; Castro-Coronel Y; Ortiz-Ortiz J; Leyva-Vázquez MA; Ortuño-Pineda C; Castro-Mora W; Illades-Aguiar B
BMC Cancer; 2021 Jan; 21(1):39. PubMed ID: 33413211
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of CLCA2 and the correlating with immune infiltrates in patients with cervical squamous cell carcinoma: A bioinformatics analysis.
Yang X; Cao JL; Yang FN; Li XF; Tao LM; Wang F
Taiwan J Obstet Gynecol; 2021 May; 60(3):480-486. PubMed ID: 33966732
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer analysis identifies protein arginine methyltransferases
Wang J; Wu M; Sun J; Chen M; Zhang Z; Yu J; Chen D
Heliyon; 2023 Dec; 9(12):e22088. PubMed ID: 38125466
[TBL] [Abstract][Full Text] [Related]
18. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
19. Bioinformatics analysis of the transcriptional expression of minichromosome maintenance proteins as potential indicators of survival in patients with cervical cancer.
Wu B; Xi S
BMC Cancer; 2021 Aug; 21(1):928. PubMed ID: 34404366
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of ProExC as a prognostic marker in oropharyngeal squamous cell carcinomas.
Mills AM; Beck AH; Pourmand N; Le QT; Kong CS
Am J Surg Pathol; 2012 Aug; 36(8):1158-64. PubMed ID: 22790856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
